GMP Flexibility For Compounders Signaled In FDA Draft Guidance
This article was originally published in The Pink Sheet Daily
Agency seeks comments on how to minimize burden of some testing requirements for registered outsourcing facilities.
You may also be interested in...
Agency releases 483 forms from a post-crises inspection push; the effort may help FDA illustrate its inspection capabilities to Congress and states and indicate the agency’s oversight plans under the new authority it has proposed.
CDER Director Woodcock says generic approvals remain inflated by applications that languished before FDA’s user fee program began, but as sponsors work through their own backlog of FDA responses, the number of ANDAs cleared by the agency appears likely to fall.
Stephen Hahn will have over 100 stocks to divest upon becoming FDA commissioner.